Jane Street Group LLC Sells 49,476 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Jane Street Group LLC decreased its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 38.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 79,537 shares of the company’s stock after selling 49,476 shares during the quarter. Jane Street Group LLC’s holdings in IDEAYA Biosciences were worth $2,520,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of IDYA. FMR LLC grew its holdings in IDEAYA Biosciences by 12.1% during the 3rd quarter. FMR LLC now owns 12,635,653 shares of the company’s stock worth $400,297,000 after acquiring an additional 1,365,570 shares during the period. Janus Henderson Group PLC boosted its position in shares of IDEAYA Biosciences by 26.7% in the 3rd quarter. Janus Henderson Group PLC now owns 5,162,376 shares of the company’s stock worth $163,518,000 after purchasing an additional 1,086,356 shares during the last quarter. State Street Corp grew its stake in shares of IDEAYA Biosciences by 15.4% during the third quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after purchasing an additional 443,640 shares during the period. Logos Global Management LP increased its holdings in IDEAYA Biosciences by 13.3% in the second quarter. Logos Global Management LP now owns 1,700,000 shares of the company’s stock valued at $59,687,000 after purchasing an additional 200,000 shares during the last quarter. Finally, RA Capital Management L.P. bought a new position in IDEAYA Biosciences during the third quarter worth about $42,681,000. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Stock Up 3.3 %

NASDAQ:IDYA opened at $25.61 on Monday. The company has a market cap of $2.21 billion, a P/E ratio of -10.99 and a beta of 0.79. IDEAYA Biosciences, Inc. has a twelve month low of $24.48 and a twelve month high of $47.74. The business has a 50 day moving average price of $28.28 and a two-hundred day moving average price of $33.98.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter in the prior year, the company posted ($0.46) earnings per share. As a group, analysts anticipate that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IDYA has been the subject of a number of recent analyst reports. UBS Group began coverage on IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a “buy” rating and a $50.00 price target for the company. Oppenheimer reiterated an “outperform” rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Stifel Nicolaus boosted their price target on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Leerink Partners downgraded IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Finally, Leerink Partnrs cut IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.67.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.